{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:53:23Z","timestamp":1792508003449,"version":"4.5.0"},"reference-count":64,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Low-dose oral minoxidil (LDOM) has emerged as a widely used off-label treatment for different types of alopecia, showing a favorable safety profile and effectiveness. Despite its growing use, it is essential to understand the possible associated adverse events (AEs) and their appropriate management to optimize this therapy. The aim of this article was to comprehensively review the AEs of LDOM treatment, describing their frequency, risk factors, affected anatomical sites, and management strategies. A search in the PubMed and EMBASE databases was performed for studies published before 31 December 2024, reporting the treatment of any type of hair loss with oral minoxidil. The most frequent AE is hypertrichosis, occurring in approximately 15% of patients, with a higher incidence in women and patients with higher doses. Fluid retention affects 1.3\u201310% of patients, particularly women, and typically occurs within 1\u20133 months of treatment. Other cardiovascular AEs, such as tachycardia or dizziness, occur in fewer than 5% of cases and are usually mild and transient. Severe AEs, including pericardial effusion, are extremely rare and often linked to compounding errors comprising an excessive dose. Management strategies include dose reduction, pharmacological interventions like diuretics for edema, and lifestyle measures such as sodium restriction. In most cases, AEs resolve without the need for treatment discontinuation. The favorable safety profile of LDOM makes it a valuable therapeutic option for alopecia, though careful patient selection, dose titration, and monitoring are essential to minimize risks.<\/jats:p>","DOI":"10.3390\/jcm14061805","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T09:38:46Z","timestamp":1741340326000},"page":"1805","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-0147","authenticated-orcid":false,"given":"Juan","family":"Jimenez-Cauhe","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, 28034 Madrid, Spain"},{"name":"Hair Disorder Unit, Grupo Pedro Ja\u00e9n, 28002 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen I.","family":"Lo Sicco","sequence":"additional","affiliation":[{"name":"The Ronald O Perelman Department of Dermatology, NYU Langone Health, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[{"name":"The Ronald O Perelman Department of Dermatology, NYU Langone Health, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hermosa-Gelbard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, 28034 Madrid, Spain"},{"name":"Hair Disorder Unit, Grupo Pedro Ja\u00e9n, 28002 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4517-507X","authenticated-orcid":false,"given":"Patricia","family":"Burgos-Blasco","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, 28034 Madrid, Spain"},{"name":"Hair Disorder Unit, Grupo Pedro Ja\u00e9n, 28002 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Melian-Olivera","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, 28034 Madrid, Spain"},{"name":"Hair Disorder Unit, Grupo Pedro Ja\u00e9n, 28002 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ortega-Quijano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, 28034 Madrid, Spain"},{"name":"Hair Disorder Unit, Grupo Pedro Ja\u00e9n, 28002 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pindado-Ortega","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, 28034 Madrid, Spain"},{"name":"Hair Disorder Unit, Grupo Pedro Ja\u00e9n, 28002 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Buendia-Casta\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, 28034 Madrid, Spain"},{"name":"Hair Disorder Unit, Grupo Pedro Ja\u00e9n, 28002 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Asz-Sigall","sequence":"additional","affiliation":[{"name":"Trichology Clinic, Hospital General Dr Manuel Gea Gonzalez, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7494","authenticated-orcid":false,"given":"Sergio","family":"Va\u00f1o-Galvan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Universidad de Alcala, 28034 Madrid, Spain"},{"name":"Hair Disorder Unit, Grupo Pedro Ja\u00e9n, 28002 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"ref_1","unstructured":"(2024, September 21). Loniten (Minoxidil Tablets USP). Pharmacia & Upjohn Company LLC, Pfizer Canada Inc.: Kirkland, QC, Canada. Available online: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=2199."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jaad.2021.02.054","article-title":"Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients","volume":"84","author":"Pirmez","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14656566.2024.2314087","article-title":"Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia","volume":"25","author":"Gupta","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.jaad.2020.11.035","article-title":"Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients","volume":"84","author":"Sanabria","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","first-page":"161","article-title":"Minoxidil oral en alopecias no androg\u00e9nicas","volume":"39","author":"Imbernon","year":"2023","journal-title":"Piel"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ad.2023.10.013","article-title":"Recomendaciones sobre el manejo cl\u00ednico de la alopecia androg\u00e9nica: Un documento de consenso del Grupo Espa\u00f1ol de Tricolog\u00eda de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda","volume":"115","author":"Garnacho","year":"2024","journal-title":"Actas Dermosifiliogr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jaad.2019.08.084","article-title":"Very low dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation","volume":"82","author":"Pirmez","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s13555-020-00448-x","article-title":"Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment","volume":"10","author":"Panchaprateep","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000531890","article-title":"Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review","volume":"9","author":"Gupta","year":"2023","journal-title":"Skin Appendage Disord."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jimenez\u2010Cauhe, J., Saceda\u2010Corralo, D., Rodrigues\u2010Barata, R., Moreno\u2010Arrones, O.M., Ortega\u2010Quijano, D., Fernandez\u2010Nieto, D., Jaen\u2010Olasolo, P., and Va\u00f1o\u2010Galvan, S. (2020). Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data. Dermatol. Ther., 33.","DOI":"10.1111\/dth.14106"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1080\/09546634.2021.1945527","article-title":"Minoxidil: A comprehensive review","volume":"33","author":"Gupta","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000525137","article-title":"There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses","volume":"8","author":"Gupta","year":"2022","journal-title":"Skin Appendage Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaad.2020.08.124","article-title":"Characterization and management of hypertrichosis induced by low-dose oral minoxidil in the treatment of hair loss","volume":"84","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaad.2021.10.048","article-title":"Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients","volume":"87","author":"Moussa","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2022.01.054","article-title":"Comment on \u201cBicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients\u201d","volume":"87","author":"Luu","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jaad.2020.10.097","article-title":"Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls","volume":"84","author":"Olamiju","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1530\/eje.0.1350604","article-title":"Spironolactone therapy in hypertrichosis","volume":"135","author":"Darendeliler","year":"1996","journal-title":"Eur. J. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nohria, A., Desai, D., Sikora, M., Mandal, S., Caplan, A., Shapiro, J., and Sicco, K.I.L. (2024). To evaluate hypertrichosis with low dose oral minoxidil and spironolactone combination therapy for alopecia. Arch. Dermatol. Res., 316.","DOI":"10.1007\/s00403-024-03261-0"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ijd.13838","article-title":"Female pattern hair loss: A pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone","volume":"57","author":"Sinclair","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pang, K.C., Nguyen, T.P., and Upreti, R. (2021). Case Report: Successful Use of Minoxidil to Promote Facial Hair Growth in an Adolescent Transgender Male. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.725269"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Shokravi, A., and Zargham, H. (2024). Facial hair enhancement with minoxidil-an off-label use. SAGE Open Med. Case Rep., 12.","DOI":"10.1177\/2050313X241231490"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaad.2020.10.032","article-title":"Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series","volume":"84","author":"Beach","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000511744","article-title":"Eyebrow Regrowth in Patients with Frontal Fibrosing Alopecia Treated with Low-Dose Oral Minoxidil","volume":"7","author":"Pirmez","year":"2021","journal-title":"Skin Appendage Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jdrv.2024.08.002","article-title":"Minoxidil-induced hypertrichosis: Pathophysiology, clinical implications, and therapeutic strategies","volume":"2","author":"Desai","year":"2024","journal-title":"JAAD Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00128071-200203090-00004","article-title":"Causes and management of hypertrichosis","volume":"3","year":"2002","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2133.2004.05785.x","article-title":"Minoxidil: Mechanisms of action on hair growth","volume":"150","author":"Messenger","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/j.1552-4604.1989.tb03307.x","article-title":"The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers","volume":"29","author":"Fleishaker","year":"1989","journal-title":"J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaad.2019.08.060","article-title":"Minoxidil 1 mg Orally versus Minoxidil 5% Solution Topically for the Treatment of Female Pattern Hair Loss: A Randomized Clinical Trial","volume":"82","author":"Ramos","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2023.10.010","article-title":"Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: A retrospective study","volume":"90","author":"Ong","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaad.2022.05.026","article-title":"Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia","volume":"88","author":"Sanabria","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.jaad.2022.06.1205","article-title":"Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil","volume":"87","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jdin.2023.08.002","article-title":"Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring","volume":"13","author":"Imhof","year":"2023","journal-title":"JAAD Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jaad.2024.10.057","article-title":"Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis","volume":"92","author":"Chen","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.abd.2023.08.016","article-title":"Oral minoxidil 7.5 mg for hair loss increases heart rate with no change in blood pressure in 24 h Holter and 24 h ambulatory blood pressure monitoring","volume":"99","author":"Sanabria","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2024.07.1472","article-title":"Prospective evaluation of blood pressure, heart rate, and side effects in hypertensive patients using low-dose oral minoxidil for hair loss","volume":"91","author":"Ramos","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"T28","DOI":"10.1016\/j.ad.2023.07.019","article-title":"Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients","volume":"115","author":"Pirmez","year":"2024","journal-title":"Actas Dermosifiliogr."},{"key":"ref_37","first-page":"228","article-title":"Oral minoxidil unrelated to arterial hypertension: Incidences due to its increasing use","volume":"40","year":"2023","journal-title":"Hipertens. Riesgo Vasc."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Godse, K., De, A., Vedamurthy, M., Shankar, D.S.K., Shah, B., Girdhar, M., Bhat, R., Ganjoo, A., Tahiliani, S., and Patil, A. (2023). Low-dose Oral Minoxidil in the Treatment of Alopecia: Evidence and Experience-based Consensus Statement of Indian Experts. Int. J. Trichology, 15.","DOI":"10.4103\/ijt.ijt_70_23"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1524-6175.2004.03585.x","article-title":"Minoxidil: An underused vasodilator for resistant or severe hypertension","volume":"6","author":"Sica","year":"2004","journal-title":"J. Clin. Hypertens."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1124\/jpet.120.000121","article-title":"KATP Channel Openers Inhibit Lymphatic Contractions and Lymph Flow as a Possible Mechanism of Peripheral Edema","volume":"376","author":"Garner","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2024.09.078","article-title":"Characterizing Low-Dose Oral Minoxidil-Induced Peripheral Edema in Alopecia Patients","volume":"92","author":"Salas","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ad.2021.09.010","article-title":"Morning Periorbital Edema Related to Low-Dose Oral Minoxidil","volume":"114","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gbadamosi, W.A., Melvin, J., and Lopez, M. (2021). Atypical Case of Minoxidil-Induced Generalized Anasarca and Pleuropericardial Effusion. Cureus, 13.","DOI":"10.7759\/cureus.15424"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jdcr.2022.07.044","article-title":"Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss","volume":"28","author":"Dlova","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ad.2021.03.003","article-title":"Serious Adverse effects From Compounding Errors With Low-Dose Oral Minoxidil for Alopecia Treatment","volume":"113","author":"Morales","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"ref_46","unstructured":"US Department of Agriculture, and US Department of Health and Human Services (2024, November 19). Dietary Guidelines for Americans, 2020\u20132025, 9th ed. Dietary Guidelines, December 2020, Available online: https:\/\/www.dietaryguidelines.gov\/sites\/default\/files\/2020-12\/Dietary_Guidelines_for_Americans_2020-2025.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","article-title":"Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction","volume":"121","author":"Hong","year":"2010","journal-title":"Circulation"},{"key":"ref_48","first-page":"e91","article-title":"Efficacy of Low-Dose Spironolactone for Hair Loss in Women","volume":"23","author":"Devjani","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1097\/00005344-198000022-00016","article-title":"Pericardial disorders occurring during open-label study of 1,869 severely hypertensive patients treated with minoxidil","volume":"2","author":"Martin","year":"1980","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.1981.128","article-title":"Minoxidil and pericardial effusion: An idiosyncratic reaction","volume":"30","author":"Reichgott","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","first-page":"2","article-title":"Low dose oral minoxidil and the conundrum of cardiovascular complications","volume":"29","author":"Ibraheim","year":"2023","journal-title":"Dermatol. Online J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/MJT.0b013e3181f5371c","article-title":"Short-term minoxidil use associated with pericardial effusion and cardiac tamponade: An uncommon presentation","volume":"19","author":"Pasala","year":"2012","journal-title":"Am. J. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jdcr.2022.08.057","article-title":"Letter in reply: Pericarditis and peripheral edema in a healthy man on low-dose oral minoxidil therapy","volume":"29","author":"Bentivegna","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jdcr.2022.09.035","article-title":"Serious complication of low-dose oral minoxidil for hair loss","volume":"30","author":"Luu","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_55","unstructured":"European Medicines Agency (2025, February 25). List of Nationally Authorised Medicinal Products: Minoxidil (Non-Topical Formulations). Available online: www.ema.europa.eu\/en\/documents\/psusa\/minoxidil-non-topical-formulations-list-nationally-authorised-medicinal-products-psusa00002066202010_en.pdf."},{"key":"ref_56","unstructured":"Vademecum Vidal (2025, February 25). Equivalencias Internacionales. Available online: www.vademecum.es\/busqueda_internacional?equivalencia=loniten."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.36849\/JDD.8027","article-title":"The Potential Impact of Off-Label Medication Use on Patient Access: A Cross-Sectional Survey of Minoxidil Availability","volume":"23","author":"Desai","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-013-0005-9","article-title":"Potential Risks of Pharmacy Compounding","volume":"13","author":"Gudeman","year":"2013","journal-title":"Drugs R D"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.36849\/JDD.8029","article-title":"Evaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral Minoxidil Therapy","volume":"23","author":"Kincaid","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jdin.2024.03.005","article-title":"Combating \u201cdread shed\u201d: The impact of overlapping topical and oral minoxidil on temporary hair shedding during oral minoxidil initiation","volume":"15","author":"Nohria","year":"2024","journal-title":"JAAD Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jaad.2010.09.724","article-title":"A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women","volume":"65","author":"Hillmann","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s13555-023-00919-x","article-title":"Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia","volume":"13","author":"Shadi","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2024.05.010","article-title":"Assessing the influence of medications with antagonistic effects on low-dose oral minoxidil in patients with alopecia: A retrospective study","volume":"17","author":"Desai","year":"2024","journal-title":"JAAD Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/ijd.17195","article-title":"Oral minoxidil and the exacerbation of alcohol hangover symptoms","volume":"63","author":"Alhanshali","year":"2024","journal-title":"Int. J. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1805\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:00Z","timestamp":1760028540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14061805"],"URL":"https:\/\/doi.org\/10.3390\/jcm14061805","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}